The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition

Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8 + T cells that st...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 13; no. 1; pp. 5440 - 11
Main Authors Motozono, Chihiro, Toyoda, Mako, Tan, Toong Seng, Hamana, Hiroshi, Goto, Yoshihiko, Aritsu, Yoshiki, Miyashita, Yusuke, Oshiumi, Hiroyuki, Nakamura, Kimitoshi, Okada, Seiji, Udaka, Keiko, Kitamatsu, Mizuki, Kishi, Hiroyuki, Ueno, Takamasa
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 21.09.2022
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8 + T cells that strongly suppress Omicron BA.1 replication in vitro. Mutagenesis analyses revealed that a G446S mutation, located just outside the N-terminus of the cognate epitope, augmented TCR recognition of this variant. In contrast, no enhanced suppression of replication is observed against cells infected with the prototype, Omicron BA.2, and Delta variants that express G446. The enhancing effect of the G446S mutation is lost when target cells are treated with inhibitors of tripeptidyl peptidase II, a protein that mediates antigen processing. These ex vivo analysis and in vitro results demonstrate that the G446S mutation in the Omicron BA.1 variant affects antigen processing/presentation and potentiates antiviral activity by vaccine-induced T cells, leading to enhanced T cell recognition towards emerging variants. Mutations in the spike of SARS-CoV-2 can result in the escape of the neutralising antibody response but may retain susceptibility to the cellular immune response. Here the authors show the G446S mutation in the spike protein of Omicron BA.1 is associated with altered antigen presentation and potentiates activation of specific T cell immunity.
AbstractList Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8+ T cells that strongly suppress Omicron BA.1 replication in vitro. Mutagenesis analyses revealed that a G446S mutation, located just outside the N-terminus of the cognate epitope, augmented TCR recognition of this variant. In contrast, no enhanced suppression of replication is observed against cells infected with the prototype, Omicron BA.2, and Delta variants that express G446. The enhancing effect of the G446S mutation is lost when target cells are treated with inhibitors of tripeptidyl peptidase II, a protein that mediates antigen processing. These ex vivo analysis and in vitro results demonstrate that the G446S mutation in the Omicron BA.1 variant affects antigen processing/presentation and potentiates antiviral activity by vaccine-induced T cells, leading to enhanced T cell recognition towards emerging variants.Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8+ T cells that strongly suppress Omicron BA.1 replication in vitro. Mutagenesis analyses revealed that a G446S mutation, located just outside the N-terminus of the cognate epitope, augmented TCR recognition of this variant. In contrast, no enhanced suppression of replication is observed against cells infected with the prototype, Omicron BA.2, and Delta variants that express G446. The enhancing effect of the G446S mutation is lost when target cells are treated with inhibitors of tripeptidyl peptidase II, a protein that mediates antigen processing. These ex vivo analysis and in vitro results demonstrate that the G446S mutation in the Omicron BA.1 variant affects antigen processing/presentation and potentiates antiviral activity by vaccine-induced T cells, leading to enhanced T cell recognition towards emerging variants.
Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8 + T cells that strongly suppress Omicron BA.1 replication in vitro. Mutagenesis analyses revealed that a G446S mutation, located just outside the N-terminus of the cognate epitope, augmented TCR recognition of this variant. In contrast, no enhanced suppression of replication is observed against cells infected with the prototype, Omicron BA.2, and Delta variants that express G446. The enhancing effect of the G446S mutation is lost when target cells are treated with inhibitors of tripeptidyl peptidase II, a protein that mediates antigen processing. These ex vivo analysis and in vitro results demonstrate that the G446S mutation in the Omicron BA.1 variant affects antigen processing/presentation and potentiates antiviral activity by vaccine-induced T cells, leading to enhanced T cell recognition towards emerging variants. Mutations in the spike of SARS-CoV-2 can result in the escape of the neutralising antibody response but may retain susceptibility to the cellular immune response. Here the authors show the G446S mutation in the spike protein of Omicron BA.1 is associated with altered antigen presentation and potentiates activation of specific T cell immunity.
Mutations in the spike of SARS-CoV-2 can result in the escape of the neutralising antibody response but may retain susceptibility to the cellular immune response. Here the authors show the G446S mutation in the spike protein of Omicron BA.1 is associated with altered antigen presentation and potentiates activation of specific T cell immunity.
Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8 + T cells that strongly suppress Omicron BA.1 replication in vitro. Mutagenesis analyses revealed that a G446S mutation, located just outside the N-terminus of the cognate epitope, augmented TCR recognition of this variant. In contrast, no enhanced suppression of replication is observed against cells infected with the prototype, Omicron BA.2, and Delta variants that express G446. The enhancing effect of the G446S mutation is lost when target cells are treated with inhibitors of tripeptidyl peptidase II, a protein that mediates antigen processing. These ex vivo analysis and in vitro results demonstrate that the G446S mutation in the Omicron BA.1 variant affects antigen processing/presentation and potentiates antiviral activity by vaccine-induced T cells, leading to enhanced T cell recognition towards emerging variants.
Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here we characterize vaccine-induced T cells specific for various SARS-CoV-2 variants and identified HLA-A*24:02-restricted CD8+ T cells that strongly suppress Omicron BA.1 replication in vitro. Mutagenesis analyses revealed that a G446S mutation, located just outside the N-terminus of the cognate epitope, augmented TCR recognition of this variant. In contrast, no enhanced suppression of replication is observed against cells infected with the prototype, Omicron BA.2, and Delta variants that express G446. The enhancing effect of the G446S mutation is lost when target cells are treated with inhibitors of tripeptidyl peptidase II, a protein that mediates antigen processing. These ex vivo analysis and in vitro results demonstrate that the G446S mutation in the Omicron BA.1 variant affects antigen processing/presentation and potentiates antiviral activity by vaccine-induced T cells, leading to enhanced T cell recognition towards emerging variants.Mutations in the spike of SARS-CoV-2 can result in the escape of the neutralising antibody response but may retain susceptibility to the cellular immune response. Here the authors show the G446S mutation in the spike protein of Omicron BA.1 is associated with altered antigen presentation and potentiates activation of specific T cell immunity.
ArticleNumber 5440
Author Hamana, Hiroshi
Kishi, Hiroyuki
Tan, Toong Seng
Motozono, Chihiro
Ueno, Takamasa
Aritsu, Yoshiki
Kitamatsu, Mizuki
Oshiumi, Hiroyuki
Okada, Seiji
Udaka, Keiko
Miyashita, Yusuke
Goto, Yoshihiko
Nakamura, Kimitoshi
Toyoda, Mako
Author_xml – sequence: 1
  givenname: Chihiro
  orcidid: 0000-0002-9027-742X
  surname: Motozono
  fullname: Motozono, Chihiro
  email: motozono@kumamoto-u.ac.jp
  organization: Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University
– sequence: 2
  givenname: Mako
  surname: Toyoda
  fullname: Toyoda, Mako
  organization: Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University
– sequence: 3
  givenname: Toong Seng
  surname: Tan
  fullname: Tan, Toong Seng
  organization: Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University
– sequence: 4
  givenname: Hiroshi
  orcidid: 0000-0002-6964-1020
  surname: Hamana
  fullname: Hamana, Hiroshi
  organization: Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama
– sequence: 5
  givenname: Yoshihiko
  surname: Goto
  fullname: Goto, Yoshihiko
  organization: Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University
– sequence: 6
  givenname: Yoshiki
  surname: Aritsu
  fullname: Aritsu, Yoshiki
  organization: Department of Applied Chemistry, Faculty of Science and Engineering, Kindai University
– sequence: 7
  givenname: Yusuke
  surname: Miyashita
  fullname: Miyashita, Yusuke
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University
– sequence: 8
  givenname: Hiroyuki
  orcidid: 0000-0003-1567-8722
  surname: Oshiumi
  fullname: Oshiumi, Hiroyuki
  organization: Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University
– sequence: 9
  givenname: Kimitoshi
  surname: Nakamura
  fullname: Nakamura, Kimitoshi
  organization: Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University
– sequence: 10
  givenname: Seiji
  orcidid: 0000-0003-3124-5206
  surname: Okada
  fullname: Okada, Seiji
  organization: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University
– sequence: 11
  givenname: Keiko
  surname: Udaka
  fullname: Udaka, Keiko
  organization: Department of Immunology, Kochi University
– sequence: 12
  givenname: Mizuki
  surname: Kitamatsu
  fullname: Kitamatsu, Mizuki
  organization: Department of Applied Chemistry, Faculty of Science and Engineering, Kindai University
– sequence: 13
  givenname: Hiroyuki
  orcidid: 0000-0002-8740-5371
  surname: Kishi
  fullname: Kishi, Hiroyuki
  organization: Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama
– sequence: 14
  givenname: Takamasa
  orcidid: 0000-0003-4852-4236
  surname: Ueno
  fullname: Ueno, Takamasa
  email: uenotaka@kumamoto-u.ac.jp
  organization: Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University
BookMark eNp9Uk1r3DAQNSWFpmn-QE-GXnpRqm9Ll8J2SdJAIJDdFnoSsjzeaGtbW8kO5N9Xu05pkkN00aB5741m5r0vjoYwQFF8JPiMYKa-JE64rBCmFDGGpUL8TXFMMSeIVJQdPYnfFacpbXE-TBPF-XHxa30H5Wpxu0LL8BPR8qb3Loah_LY4I2Xa-d9QXnIuV2U_jXb0ObMLIwyjtyOk0ubg3kfblWvkoOvKCC5sBr8HfijetrZLcPp4nxQ_Ls7Xy-_o-ubyarm4Rk6QakSNbQlTtpWE1FaCcLZpZKtVQwVoVVd1zWQrKW-E07qxMmd4paGybUtxRSk7Ka5m3SbYrdlF39v4YIL15vAQ4sbYOHrXgVFOOGG1xg4DrzGtRas5MIkt4UJilbW-zlq7qe6hcbnR3Nwz0eeZwd-ZTbg3mmsqhcwCnx8FYvgzQRpN79N-MnaAMCVDKyI1I0qKDP30AroNUxzyqA6ovCBOq4xSMypvJaUIrXF-XkSu7ztDsNl7wMweMNkD5uABwzOVvqD-6-NVEptJKYOHDcT_v3qF9Rce1MSI
CitedBy_id crossref_primary_10_1016_j_celrep_2024_113887
crossref_primary_10_1128_jvi_01162_22
crossref_primary_10_1038_s41467_024_54734_9
crossref_primary_10_1016_j_isci_2023_106940
crossref_primary_10_1016_j_heliyon_2023_e20076
crossref_primary_10_3390_vaccines11020314
crossref_primary_10_1016_j_virol_2023_109850
crossref_primary_10_2222_jsv_73_173
crossref_primary_10_3389_fimmu_2022_1081047
crossref_primary_10_1038_s41598_024_77969_4
crossref_primary_10_1038_s41467_023_43004_9
crossref_primary_10_1016_j_cbi_2022_110244
crossref_primary_10_1016_j_ebiom_2024_105185
crossref_primary_10_1093_immadv_ltad005
Cites_doi 10.1016/j.cell.2022.04.035
10.1038/s10038-020-0771-5
10.1016/j.cell.2020.05.015
10.1016/S0968-0004(99)01435-8
10.1038/s41586-021-04389-z
10.1016/j.celrep.2021.110218
10.1038/s41586-022-04411-y
10.1016/j.cell.2022.01.015
10.1038/s41586-022-04460-3
10.1038/s41591-022-01700-x
10.1016/j.xcrm.2021.100355
10.1016/0092-8674(91)90037-Y
10.1038/s41586-021-04387-1
10.1016/j.cell.2022.01.029
10.1016/j.gendis.2021.05.006
10.1016/j.bbrc.2016.05.015
10.1084/jem.20031982
10.4049/jimmunol.175.7.4618
10.1038/s41590-020-0782-6
10.1038/s41586-021-04385-3
10.1038/s41586-022-04462-1
10.1007/BF00216838
10.1016/j.chom.2021.06.006
10.1038/nri3084
10.1172/JCI32047
10.1007/s00251-006-0185-3
10.1016/j.isci.2021.102311
10.1126/sciimmunol.abo2202
10.1172/JCI145476
ContentType Journal Article
Copyright The Author(s) 2022
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
Copyright_xml – notice: The Author(s) 2022
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
DBID C6C
AAYXX
CITATION
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
5PM
DOA
DOI 10.1038/s41467-022-33068-4
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
Coronavirus Research Database
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 11
ExternalDocumentID oai_doaj_org_article_8c5c5a990c0e4b02b5f94e360a145608
PMC9492656
10_1038_s41467_022_33068_4
GrantInformation_xml – fundername: MEXT | Japan Society for the Promotion of Science (JSPS)
  grantid: 22H02877; 19K07623; 22K07089; 19H03703; 22H03119
  funderid: https://doi.org/10.13039/501100001691
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: 21fk0410046; 20fk0108539h0001; 20fk0108451s0101
  funderid: https://doi.org/10.13039/100009619
– fundername: Takeda Science Foundation
  funderid: https://doi.org/10.13039/100007449
– fundername: IMAI MEMORIAL TRUST FOR AIDS RESERARCH Shin-Nihon Foundation of Advanced Medical Research
– fundername: An intramural grant from Kumamoto University COVID-19 Research Projects (AMABIE)
– fundername: ;
– fundername: ;
  grantid: 21fk0410046; 20fk0108539h0001; 20fk0108451s0101
– fundername: ;
  grantid: 22H02877; 19K07623; 22K07089; 19H03703; 22H03119
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LK8
M1P
M48
M7P
M~E
NAO
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AZQEC
C1K
COVID
DWQXO
FR3
GNUQQ
H94
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
RC3
SOI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c517t-daf138af611ba6e5cadd6f98d25e98b7bb36f624d5c99da698d479e7aff207223
IEDL.DBID 7X7
ISSN 2041-1723
IngestDate Wed Aug 27 01:32:18 EDT 2025
Thu Aug 21 18:39:51 EDT 2025
Fri Jul 11 11:55:43 EDT 2025
Sat Aug 23 13:02:12 EDT 2025
Tue Jul 01 00:58:26 EDT 2025
Thu Apr 24 23:06:36 EDT 2025
Fri Feb 21 02:38:17 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-daf138af611ba6e5cadd6f98d25e98b7bb36f624d5c99da698d479e7aff207223
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8740-5371
0000-0002-9027-742X
0000-0002-6964-1020
0000-0003-3124-5206
0000-0003-1567-8722
0000-0003-4852-4236
OpenAccessLink https://www.proquest.com/docview/2716391427?pq-origsite=%requestingapplication%
PQID 2716391427
PQPubID 546298
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_8c5c5a990c0e4b02b5f94e360a145608
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9492656
proquest_miscellaneous_2716931865
proquest_journals_2716391427
crossref_citationtrail_10_1038_s41467_022_33068_4
crossref_primary_10_1038_s41467_022_33068_4
springer_journals_10_1038_s41467_022_33068_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-21
PublicationDateYYYYMMDD 2022-09-21
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-21
  day: 21
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Mashiba (CR27) 2007; 59
Viana (CR1) 2022; 603
Keeton (CR7) 2022; 603
Gao (CR9) 2022; 28
Cele (CR2) 2022; 602
Motozono (CR13) 2021; 29
Milicic (CR17) 2005; 175
Neefjes, Jongsma, Paul, Bakke (CR11) 2011; 11
Suzuki (CR28) 2022; 603
Draenert (CR12) 2004; 199
Del Val, Schlicht, Ruppert, Reddehase, Koszinowski (CR19) 1991; 66
Planas (CR4) 2022; 602
Cao (CR3) 2022; 602
Naranbhai (CR10) 2022; 185
Kimura (CR15) 2022; 38
CR8
Tarke (CR6) 2022; 185
Tomkinson (CR20) 1999; 24
Le Gall, Stamegna, Walker (CR18) 2007; 117
Kiyotani, Toyoshima, Nemoto, Nakamura (CR14) 2020; 65
Hamana, Shitaoka, Kishi, Ozawa, Muraguchi (CR16) 2016; 474
Tarke (CR5) 2021; 2
CR23
Peng (CR25) 2020; 21
CR21
Grifoni (CR24) 2020; 181
Yamasoba (CR29) 2022; 185
Hu (CR22) 2022; 9
Karaki (CR26) 1993; 37
S Le Gall (33068_CR18) 2007; 117
A Tarke (33068_CR6) 2022; 185
Y Gao (33068_CR9) 2022; 28
T Mashiba (33068_CR27) 2007; 59
D Planas (33068_CR4) 2022; 602
R Viana (33068_CR1) 2022; 603
A Grifoni (33068_CR24) 2020; 181
K Kiyotani (33068_CR14) 2020; 65
A Milicic (33068_CR17) 2005; 175
33068_CR23
S Cele (33068_CR2) 2022; 602
B Tomkinson (33068_CR20) 1999; 24
33068_CR21
I Kimura (33068_CR15) 2022; 38
S Karaki (33068_CR26) 1993; 37
R Suzuki (33068_CR28) 2022; 603
D Yamasoba (33068_CR29) 2022; 185
Y Peng (33068_CR25) 2020; 21
H Hamana (33068_CR16) 2016; 474
C Motozono (33068_CR13) 2021; 29
M Del Val (33068_CR19) 1991; 66
33068_CR8
J Neefjes (33068_CR11) 2011; 11
V Naranbhai (33068_CR10) 2022; 185
C Hu (33068_CR22) 2022; 9
Y Cao (33068_CR3) 2022; 602
R Draenert (33068_CR12) 2004; 199
A Tarke (33068_CR5) 2021; 2
R Keeton (33068_CR7) 2022; 603
References_xml – volume: 185
  start-page: 2103
  year: 2022
  end-page: 2115.e2119
  ident: CR29
  article-title: Virological characteristics of the SARS-CoV-2 omicron BA.2 spike
  publication-title: Cell
  doi: 10.1016/j.cell.2022.04.035
– volume: 65
  start-page: 569
  year: 2020
  end-page: 575
  ident: CR14
  article-title: Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2
  publication-title: J. Hum. Genet.
  doi: 10.1038/s10038-020-0771-5
– volume: 181
  start-page: 1489
  year: 2020
  end-page: 1501.e1415
  ident: CR24
  article-title: Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
– volume: 24
  start-page: 355
  year: 1999
  end-page: 359
  ident: CR20
  article-title: Tripeptidyl peptidases: enzymes that count
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/S0968-0004(99)01435-8
– volume: 602
  start-page: 671
  year: 2022
  end-page: 675
  ident: CR4
  article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
  publication-title: Nature
  doi: 10.1038/s41586-021-04389-z
– volume: 38
  start-page: 110218
  year: 2022
  ident: CR15
  article-title: The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.110218
– volume: 603
  start-page: 679
  year: 2022
  end-page: 686
  ident: CR1
  article-title: Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
  publication-title: Nature
  doi: 10.1038/s41586-022-04411-y
– volume: 185
  start-page: 847
  year: 2022
  end-page: 859.e811
  ident: CR6
  article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.015
– volume: 603
  start-page: 488
  year: 2022
  end-page: 492
  ident: CR7
  article-title: T cell responses to SARS-CoV-2 spike cross-recognize Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04460-3
– volume: 28
  start-page: 472
  year: 2022
  end-page: 476
  ident: CR9
  article-title: Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01700-x
– volume: 2
  start-page: 100355
  year: 2021
  ident: CR5
  article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2021.100355
– volume: 66
  start-page: 1145
  year: 1991
  end-page: 1153
  ident: CR19
  article-title: Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90037-Y
– ident: CR8
– volume: 602
  start-page: 654
  year: 2022
  end-page: 656
  ident: CR2
  article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
  publication-title: Nature
  doi: 10.1038/s41586-021-04387-1
– volume: 185
  start-page: 1041
  year: 2022
  end-page: 1051.e1046
  ident: CR10
  article-title: T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.029
– volume: 9
  start-page: 216
  year: 2022
  end-page: 229
  ident: CR22
  article-title: Identification of cross-reactive CD8(+) T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
  publication-title: Genes Dis.
  doi: 10.1016/j.gendis.2021.05.006
– volume: 474
  start-page: 709
  year: 2016
  end-page: 714
  ident: CR16
  article-title: A novel, rapid and efficient method of cloning functional antigen-specific T-cell receptors from single human and mouse T-cells
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2016.05.015
– ident: CR23
– volume: 199
  start-page: 905
  year: 2004
  end-page: 915
  ident: CR12
  article-title: Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20031982
– ident: CR21
– volume: 175
  start-page: 4618
  year: 2005
  end-page: 4626
  ident: CR17
  article-title: CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.175.7.4618
– volume: 21
  start-page: 1336
  year: 2020
  end-page: 1345
  ident: CR25
  article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-020-0782-6
– volume: 602
  start-page: 657
  year: 2022
  end-page: 663
  ident: CR3
  article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
  publication-title: Nature
  doi: 10.1038/s41586-021-04385-3
– volume: 603
  start-page: 700
  year: 2022
  end-page: 705
  ident: CR28
  article-title: Attenuated fusogenicity and pathogenicity of SARS-CoV-2 omicron variant
  publication-title: Nature
  doi: 10.1038/s41586-022-04462-1
– volume: 37
  start-page: 139
  year: 1993
  end-page: 142
  ident: CR26
  article-title: HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies
  publication-title: Immunogenetics
  doi: 10.1007/BF00216838
– volume: 29
  start-page: 1124
  year: 2021
  end-page: 1136
  ident: CR13
  article-title: SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.06.006
– volume: 11
  start-page: 823
  year: 2011
  end-page: 836
  ident: CR11
  article-title: Towards a systems understanding of MHC class I and MHC class II antigen presentation
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3084
– volume: 117
  start-page: 3563
  year: 2007
  end-page: 3575
  ident: CR18
  article-title: Portable flanking sequences modulate CTL epitope processing
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI32047
– volume: 59
  start-page: 197
  year: 2007
  end-page: 209
  ident: CR27
  article-title: Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine
  publication-title: Immunogenetics
  doi: 10.1007/s00251-006-0185-3
– volume: 2
  start-page: 100355
  year: 2021
  ident: 33068_CR5
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2021.100355
– ident: 33068_CR21
  doi: 10.1016/j.isci.2021.102311
– volume: 21
  start-page: 1336
  year: 2020
  ident: 33068_CR25
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-020-0782-6
– volume: 38
  start-page: 110218
  year: 2022
  ident: 33068_CR15
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.110218
– volume: 602
  start-page: 654
  year: 2022
  ident: 33068_CR2
  publication-title: Nature
  doi: 10.1038/s41586-021-04387-1
– volume: 603
  start-page: 488
  year: 2022
  ident: 33068_CR7
  publication-title: Nature
  doi: 10.1038/s41586-022-04460-3
– volume: 199
  start-page: 905
  year: 2004
  ident: 33068_CR12
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20031982
– volume: 185
  start-page: 847
  year: 2022
  ident: 33068_CR6
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.015
– volume: 65
  start-page: 569
  year: 2020
  ident: 33068_CR14
  publication-title: J. Hum. Genet.
  doi: 10.1038/s10038-020-0771-5
– volume: 603
  start-page: 700
  year: 2022
  ident: 33068_CR28
  publication-title: Nature
  doi: 10.1038/s41586-022-04462-1
– volume: 602
  start-page: 657
  year: 2022
  ident: 33068_CR3
  publication-title: Nature
  doi: 10.1038/s41586-021-04385-3
– volume: 29
  start-page: 1124
  year: 2021
  ident: 33068_CR13
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.06.006
– volume: 175
  start-page: 4618
  year: 2005
  ident: 33068_CR17
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.175.7.4618
– volume: 24
  start-page: 355
  year: 1999
  ident: 33068_CR20
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/S0968-0004(99)01435-8
– volume: 185
  start-page: 2103
  year: 2022
  ident: 33068_CR29
  publication-title: Cell
  doi: 10.1016/j.cell.2022.04.035
– volume: 59
  start-page: 197
  year: 2007
  ident: 33068_CR27
  publication-title: Immunogenetics
  doi: 10.1007/s00251-006-0185-3
– volume: 11
  start-page: 823
  year: 2011
  ident: 33068_CR11
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3084
– volume: 37
  start-page: 139
  year: 1993
  ident: 33068_CR26
  publication-title: Immunogenetics
  doi: 10.1007/BF00216838
– volume: 9
  start-page: 216
  year: 2022
  ident: 33068_CR22
  publication-title: Genes Dis.
  doi: 10.1016/j.gendis.2021.05.006
– ident: 33068_CR8
  doi: 10.1126/sciimmunol.abo2202
– volume: 181
  start-page: 1489
  year: 2020
  ident: 33068_CR24
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
– volume: 28
  start-page: 472
  year: 2022
  ident: 33068_CR9
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01700-x
– volume: 474
  start-page: 709
  year: 2016
  ident: 33068_CR16
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2016.05.015
– volume: 602
  start-page: 671
  year: 2022
  ident: 33068_CR4
  publication-title: Nature
  doi: 10.1038/s41586-021-04389-z
– volume: 117
  start-page: 3563
  year: 2007
  ident: 33068_CR18
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI32047
– volume: 603
  start-page: 679
  year: 2022
  ident: 33068_CR1
  publication-title: Nature
  doi: 10.1038/s41586-022-04411-y
– ident: 33068_CR23
  doi: 10.1172/JCI145476
– volume: 185
  start-page: 1041
  year: 2022
  ident: 33068_CR10
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.029
– volume: 66
  start-page: 1145
  year: 1991
  ident: 33068_CR19
  publication-title: Cell
  doi: 10.1016/0092-8674(91)90037-Y
SSID ssj0000391844
Score 2.4777954
Snippet Although the Omicron variant of the SARS-CoV-2 virus shows resistance to neutralizing antibody, it retains susceptibility to the cellular immune response. Here...
Mutations in the spike of SARS-CoV-2 can result in the escape of the neutralising antibody response but may retain susceptibility to the cellular immune...
SourceID doaj
pubmedcentral
proquest
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 5440
SubjectTerms 13
13/1
13/31
42
42/109
42/70
45/22
45/23
45/44
45/77
631/250/1619/554
631/250/254
631/250/255/2514
631/326/596/4130
64/60
82/80
82/83
96
Antibodies
Antibody response
Antigen presentation
Antigen processing
Antigens
Antiviral activity
Antiviral drugs
CD8 antigen
Cell activation
Cell recognition
COVID-19
Disease resistance
Epitopes
Histocompatibility antigen HLA
Humanities and Social Sciences
Immune response
Immune response (cell-mediated)
Immune system
Lymphocytes
Lymphocytes T
multidisciplinary
Mutagenesis
Mutation
N-Terminus
Peptidase
Peptidases
Proteins
Recognition
Replication
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Spike protein
T cell receptors
Tripeptidylpeptidase II
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LaxQxGA9SELyITxytEsGbxk4m7-O2WIuggttKPYUkk-DSdmZxdw_-937JzK6dgnrxOskwyS9fvsd8L4ReBRMbyqIgLUuJ8KCyfzcwIoPjSdDEQsmt-vhJnpzxD-fi_FqrrxwTNpQHHoA70EEE4YBnhjpyXzdeJMMjk7WjIPuHNF-QedeMqcKDmQHThY9ZMjXTByteeEIJXgc1WRM-kUSlYP9Ey7wZI3nDUVrkz_E9dHdUHPFsWPB9dCt2D9DtoZXkz4foG5w3ns--zMlR_5U0-PNVjrTr8OHsLcWr5eIi4vdgk83x1WZwvuNlv86RQlnXxADvIkf7XuJTkn_l411cUd89QmfH706PTsjYNoEEQdWatC5Rpl2SlHonowjAwmQyum1ENNor75lMsuGtCMa0TsIIVyYql1JTK1AXHqO9ru_iE4RTEMk5r6n0inNvtBG1YxzMxCS1N6FCdAuhDWNN8dza4tIW3zbTdoDdAuy2wG55hV7v3lkOFTX-Ovswn8xuZq6GXR4AjdiRRuy_aKRC-9tzteMVXdkGLEWgEt6oCr3cDcPlyjC7LvabYY4BridFhdSEHiYLmo50i--lTLfJtRiFrNCbLeX8_vifN_z0f2z4GbrTZErP3jO6j_bWPzbxOShPa_-i3JNfbU4SyA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA-1IvgifuJqlQi-aepm8_0gci3WIlTB60l9Ckk2qYfX3fM-wP73Jtndkyu1r5uEzc5H5jc7kxkAXjvlK0w8QzUJAVEnUnzXEcSdoYHhQFy-W3XyhR9P6OczdrYDhnZHPQGX17p2qZ_UZDHb__P78kNU-PfdlXH5bkmzuue89IiAJaK3wO1omURS1JMe7ueTmajo0ND-7sz1S7fsUy7jv4U9r2ZOXgmfZqt0dB_c6-EkHHX8fwB2fPMQ3OkaTF4-Aj-iFMDx6NsYHbbfUQW_XqT8uwYejPYxXM6nvzz8FD21MbxYdyF5OG9XKX8oIVAYiT5NOcAzeIrSD364yTZqm8dgcvTx9PAY9c0UkGNYrFBtAibSBI6xNdwzFw82HpSsK-aVtMJawgOvaM2cUrXhcYQK5YUJoSpFBBFPwG7TNv4pgMGxYIyVmFtBqVVSsdIQGp3HwKVVrgB4IKF2faXx1PBipnPEm0jdkV1HsutMdk0L8GazZt7V2bhx9kHizGZmqpGdH7SLc92rnJaOOWaitXWlp7asLAuKesJLgyNqLGUB9ga-6kHudBX9xygltBIFeLUZjiqXyGwa3667OSqehZwVQGzJw9aGtkea6c9cvFulCo2MF-DtIDn_Xv7_D352816fg7tVkuEULcN7YHe1WPsXESyt7MusAX8BBH4OJw
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bbxQhFCa1xsQX4zWOVoOJb4oO14HH7ca2aaImbmvqEwEG6sZ2ZtPdffDfC8zFTGNN-jocMnA4Bw6cjw8A3jrlCaaeo5qGgJirUn7XUSScYYHjQF2-W_X5izg6Zcdn_GwHkOEuTAbtZ0rLPE0P6LCPa5ZdOmPPY5QrEbsD7ibq9mTVczEfz1US47lkrL8fU1L5j6qTNShT9U_iy-voyGsp0rzyHDwED_qQEc66Rj4CO755DO51j0j-fgJ-xJGGi9m3BZq33xGBXy8Txq6B-7MPGK5Xy18eHsYOLODltku7w1W7SRihFGXCqNhlwvlewBOUDvHhiChqm6fg9ODTyfwI9Q8mIMdxtUG1CZhKEwTG1gjPXZy8RFCyJtwraStrqQiCsJo7pWojYgmrlK9MCKSsYqDwDOw2beOfAxgcD8ZYiYWNSrZKKl4ayuIGMQhplSsAHlSoXc8mnh61uNA5q02l7tSuo9p1VrtmBXg31ll1XBr_ld5PIzNKJh7s_KG9Ote9XWjpuOMmrqiu9MyWxPKgmKeiNDhGhqUswN4wrrp3zrUmcY8YrYSRqgBvxuLoVknNpvHttpNRcb4TvADVxB4mDZqWNMufmaBbJRZGLgrwfrCcvz-_ucMvbif-EtwnyaZThgzvgd3N1da_igHSxr7OHvEHBlIIww
  priority: 102
  providerName: Springer Nature
Title The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition
URI https://link.springer.com/article/10.1038/s41467-022-33068-4
https://www.proquest.com/docview/2716391427
https://www.proquest.com/docview/2716931865
https://pubmed.ncbi.nlm.nih.gov/PMC9492656
https://doaj.org/article/8c5c5a990c0e4b02b5f94e360a145608
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0IJNSLwgPkVgVEbiDczi-PsJpdW6qdIGWjdUniLbsaFiS8raPvDvsZ20UyexF0eyHcW5L5_vzncAfLDKFZg4hmriPaJWRP-uJYhbTT3Dnth0t-r0jJ9c0smMzXqD27IPq9zIxCSo69ZGG_lhERR7ojAtxJfFHxSrRkXval9C4yHYj6nLYkiXmImtjSVmP5eU9ndlciIPlzRJhhTCHpRliejOfpTS9u_omncjJe-4S9MuNH4KnvTqIyw7fD8DD1zzHDzqCkr-fQF-BKzDaXk-RaP2Oyrg1-sYb9fAYfkZw-Vi_tvB43Aym8LrdeeCh4t2FeOFosYJA5DnMeb3Cl6gaNCH2-iitnkJLsdHF6MT1BdPQJZhsUK19phI7TnGRnPHbBBk3CtZF8wpaYQxhHte0JpZpWrNwwgVygntfZGLoDS8AntN27jXAHrLvNZGYm4EpUZJxXJNaDgsei6NshnAGxBWts8sHgtcXFXJw01k1YG9CmCvEtgrmoGP23cWXV6Ne2cPI2a2M2NO7NTR3vyseharpGWW6bC72txRkxeGeUUd4bnGQUvMZQYONnitekZdVrdklYH32-HAYhHMunHtupujguzjLANihx52FrQ70sx_pWTdKmZkZDwDnzaUc_vx___wm_vX-hY8LiINR-8YPgB7q5u1exeUo5UZJA4IrRwfD8B-WU6mk_AcHp19Ow-9Iz4aJLNDaE-p_AfynRG3
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIQQviKsIDDASPIFZ7NiO_YBQNxgduyDRDpWnYDs2VGxJWVuh_Sl-I7ZzmTqJve01dhTn3O1z_B0AXhhpCc4sQ2XmHKImD_ldkyFuFHUMu8zEu1UHh3x4RD9N2GQN_O3uwoSyys4mRkNd1iackW8SH9hnElOSv5v9RqFrVMiudi00GrHYs2d__JZt_nb3vefvS0J2Poy3h6jtKoAMw_kClcrhTCjHMdaKW2a8hnMnRUmYlULnWmfccUJLZqQsFfcjNJc2V86RNCcB6MCb_Gve8aZBo_JJ3p_pBLR1QWl7NyfNxOacRksUS-Z9cC4QXfF_sU3ASmx7sTLzQno2er2d2-BWG67CQSNfd8Care6C600Dy7N74JuXMjgafBmh7forIvDzSajvq-DW4A2G89n0l4Uf_U5wBE-WTcofzupFqE8KES70TJ2GGuNjOEYhgQD7aqa6ug-OroSsD8B6VVf2IYDOMKeUFpjrnFIthWSpyqjfnDoutDQJwB0JC9MimYeGGsdFzKhnomjIXniyF5HsBU3Aq_6dWYPjcensrcCZfmbA4I4P6tMfRavShTDMMOW9uUkt1SnRzElqM54q7KPSVCRgo-Nr0RqGeXEuxgl43g97lQ5kVpWtl80c6W0tZwnIV-RhZUGrI9X0ZwQHlwEBkvEEvO4k5_zj___hR5ev9Rm4MRwf7Bf7u4d7j8FNEuQ5ZObwBlhfnC7tEx-YLfTTqA0QfL9q9fsHoIZJXA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIhAXxFMEChgJThAaP2MfENq2LC2FgmiLlpOxHRtWtMnS3RXqX-PXYTvJVluJ3nqNHcWZl2c8n2cAeGalw4g4llfE-5zaMuZ3Lcm51dQz5IlNd6s-7vHtQ_p-xEYr4G9_FybCKnubmAx11dh4Rr6Og2NPJKIhVPcdLOLz1vDN5HceO0jFTGvfTqMVkV13-ieEb9PXO1uB188xHr492NzOuw4DuWWonOWV9ogI7TlCRnPHbNB27qWoMHNSmNIYwj3HtGJWykrzMEJL6UrtPS5KHIseBPN_pSQMRR0rR-XifCdWXheUdvd0CiLWpzRZpQSfD466yOnSXphaBiz5uedRmudStWkHHN4ENzrXFQ5aWbsFVlx9G1xtm1me3gHfgsTB_cGX_Xyz-Zpj-Ok4Yv1quDF4heB0Mv7l4LsQFe7D43mb_oeTZhaxStHbhYHB44g3PoIHeUwmwAWyqanvgsNLIes9sFo3tbsPoLfMa20E4qak1EghWaEJDYGq58JImwHUk1DZrqp5bK5xpFJ2nQjVkl0FsqtEdkUz8GLxzqSt6XHh7I3ImcXMWI87PWhOfqhOvZWwzDIddnZbOGoKbJiX1BFeaBQ81EJkYK3nq-qMxFSdiXQGni6Gg3pHMuvaNfN2jgx2l7MMlEvysLSg5ZF6_DMVCpexGiTjGXjZS87Zx___ww8uXusTcC0onvqws7f7EFzHUZxjkg6tgdXZydw9Cj7azDxOygDB98vWvn8ELk2S
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+SARS-CoV-2+Omicron+BA.1+spike+G446S+mutation+potentiates+antiviral+T-cell+recognition&rft.jtitle=Nature+communications&rft.au=Motozono%2C+Chihiro&rft.au=Toyoda%2C+Mako&rft.au=Tan%2C+Toong+Seng&rft.au=Hamana%2C+Hiroshi&rft.date=2022-09-21&rft.pub=Nature+Publishing+Group&rft.eissn=2041-1723&rft.volume=13&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-022-33068-4&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon